CHILDHOOD MDS TREATED WITH AML REGIMENS

被引：0
|
作者：
HASLE, H
KERNDRUP, G
机构：
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 1995年 / 40卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [31] INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HIGH-RISK MDS AND AML TREATED WITH AZACITIDINE
    Pomares Marin, H.
    Arnan Sangerman, M.
    Sanchez-Ortega Sanchez, I.
    Duarte Palomino, R. D.
    LEUKEMIA RESEARCH, 2015, 39 : S145 - S146
  • [32] Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate
    Gore, SD
    Baylin, SB
    Dauses, T
    Grever, MR
    Jiemjit, A
    Manning, J
    Miller, CB
    Murgo, AJ
    Zwiebel, JA
    Herman, JG
    BLOOD, 2004, 104 (11) : 137A - 137A
  • [33] Emerging agents and regimens for AML
    Hongtao Liu
    Journal of Hematology & Oncology, 14
  • [34] Connect MDS and AML: The myelodysplastie syndromes (MDS) and acute myeloid leukemia (AML) disease registry.
    Steensma, David P.
    Abedi, Mehrdad
    Attar, Eyal C.
    Bejar, Rafael
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Ma, Xlaomei
    Maciejowski, Jaroslaw P.
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael
    Scott, Bart L.
    Sekenos, Mikkael A.
    Thompson, Michael A.
    Zernovak, Oleg
    Sugrue, Mary M.
    Swern, Arlene S.
    Nifonecker, Melissa
    Erba, Harry Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens
    Bainschab, A.
    Quehenberger, F.
    Greinix, H. T.
    Krause, R.
    Woelfler, A.
    Sill, H.
    Zebisch, A.
    Oncology Research and Treatment, 2015, 38 : 73 - 74
  • [36] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
    Ohm, AC
    Hast, R
    Bernell, P
    Celsing, F
    Dahl, IM
    Dybedal, I
    Lindberg, G
    Linder, O
    Löfvenberg, E
    Nilsson-Ehle, H
    Samuelsson, J
    Tangen, J
    Turesson, I
    Wallvik, J
    Winquist, I
    Öberg, G
    Björkholm, M
    Hellström-Lindberg, E
    BLOOD, 2000, 96 (11) : 148A - 148A
  • [37] Emerging agents and regimens for AML
    Liu, Hongtao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [38] Acute myeloid leukemia (AML) - Type chemotherapy for newly diagnosed children with myelodysplastic syndrome (MDS): A Japanese childhood MDS study group trial MDS99.
    Ohtsuka, Y
    Manabe, A
    Okamura, J
    Kojima, S
    Ohara, A
    Tuchida, M
    Ikuta, K
    Hibi, S
    Kawa, K
    Yabe, M
    Watanabe, A
    Ueda, K
    Nakazawa, S
    Miyazaki, S
    Nakahata, T
    BLOOD, 2004, 104 (11) : 265B - 265B
  • [39] Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
    Sebert, Marie
    Freiman, Lucie
    Chaffaut, Cendrine
    Guerci, Agnes
    Peterlin, Pierre
    Thepot, Sylvain
    Beyne-Rauzy, Odile
    Park, Sophie
    Cluzeau, Thomas
    Chermat, Fatiha
    Fenaux, Pierre
    Preudhomme, Claude
    Clappier, Emmanuelle
    Chevret, Sylvie
    Ades, Lionel
    Duployez, Nicolas
    Duchmann, Matthieu
    LEUKEMIA, 2024, 38 (04) : 918 - 922
  • [40] Animal models for AML, MDS and MPN
    Kitamura, Toshio
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 197 - 197
12345